Niagen Bioscience, Inc. — Proxy Solicitation & Information Statement 2021

Apr 21, 2021

DEFA14A 1 cdxcdefa14a_apr2021.htm DEFINITIVE ADDITIONAL MATERIALS Document created using Blueprint(R) - powered by Issuer Direct - www.issuerdirect.com Copyright 2021 Issuer Direct Corporation cdxcdefa14a_apr2021

style header

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

SCHEDULE 14A

Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

| Filed

by the Registrant
Filed
by a party other than the Registrant	☐
Check
the appropriate box:
☐	Preliminary
Proxy Statement
☐	Confidential, For Use of the Commission Only (as Permitted by Rule
14a-6(e)(2))
☐	Definitive
Proxy Statement
☒	Definitive
Additional Materials
☐	Soliciting
Material Pursuant to § 240.14a-12

CHROMADEX CORPORATION

(Name of Registrant as Specified in its Charter)

(Name of Person(s) Filing Proxy Statement, if other than the Registrant)

| Payment

of Filing Fee (Check the appropriate box):
☒	No fee
required
☐	Fee
computed on table below per Exchange Act Rules 14a-6(i)(1) and
0-11.
(1)	Title
of each class of securities to which transaction applies:
(2)	Aggregate
number of securities to which transaction applies:
(3)	Per
unit price or other underlying value of transaction computed
pursuant to Exchange Act Rule 0-11 (set forth the amount on which
the filing fee is calculated and state how it was
determined):
(4)	Proposed
maximum aggregate value of transaction:
(5)	Total
fee paid:
☐	Fee
paid previously with preliminary materials:
☐	Check
box if any part of the fee is offset as provided by Exchange Act
Rule 0-11(a)(2) and identify the filing for which the offsetting
fee was paid previously. Identify the previous filing by
registration statement number, or the Form or Schedule and the date
of its filing.
(1)	Amount
previously paid:
(2)	Form,
Schedule or Registration Statement No.:
(3)	Filing
Party:
(4)	Date
Filed:

style footer

page break line

page break line

page break